Dawoud Sulaiman1, Jingyuan Li2, Asokan Devarajan3, Christine Marie Cunningham2, Min Li2, Gregory A Fishbein4, Alan M Fogelman5, Mansoureh Eghbali2, Srinivasa T Reddy6. 1. Department of Medicine, Division of Cardiology, David Geffen School of Medicine, University of California, Los Angeles, United States of America; Molecular Toxicology Interdepartmental Degree Program, University of California, Los Angeles, United States of America. 2. Department of Anesthesiology, Division of Molecular Medicine, David Geffen School of Medicine, University of California, Los Angeles, United States of America. 3. Department of Medicine, Division of Cardiology, David Geffen School of Medicine, University of California, Los Angeles, United States of America. Electronic address: ADevarajan@mednet.ucla.edu. 4. Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, United States of America. 5. Department of Medicine, Division of Cardiology, David Geffen School of Medicine, University of California, Los Angeles, United States of America. 6. Department of Medicine, Division of Cardiology, David Geffen School of Medicine, University of California, Los Angeles, United States of America; Molecular Toxicology Interdepartmental Degree Program, University of California, Los Angeles, United States of America. Electronic address: SReddy@mednet.ucla.edu.
Abstract
OBJECTIVE: To investigate the novel role of Paraoxonase 2 (PON2) in modulating acute myocardial ischemia-reperfusion injury (IRI). APPROACH: IRI was induced both in vivo and ex vivo in male, C57BL6/J (WT) and PON2-deficient (PON-def) mice. In addition, in vitro hypoxia-reoxygenation injury (HRI) was induced in H9c2 cells expressing empty vector (H9c2-EV) or human PON2 (H9c2-hPON2) ± LY294002 (a potent PI3K inhibitor). Infarct size, PON2 gene expression, mitochondrial calcium retention capacity (CRC), reactive oxygen species (ROS) generation, mitochondrial membrane potential, CHOP and pGSK-3β protein levels, and cell apoptosis were evaluated. RESULTS: PON2 gene expression is upregulated in WT mice following in vivo IRI. PON2-def mice exhibit a 2-fold larger infarct, increased CHOP levels, and reduced pGSK-3β levels compared to WT controls. Global cardiac mitochondria isolated from PON2-def mice exhibit reduced CRC and increased ROS production. Cardiomyocytes isolated from PON2-def mice subjected to ex vivo IRI have mitochondria with reduced CRC (also seen under non-IRI conditions), and increased ROS generation and apoptosis compared to WT controls. PON2 knockdown in H9c2 cells subjected to HRI leads to an increase in mitochondrial membrane depolarization. H9c2-hPON2 cells exhibit i) improvement in mitochondrial membrane potential, pGSK-3β levels and mitochondrial CRC, and ii) decrease in CHOP levels, mitochondrial ROS generation and cell apoptosis, when compared to H9c2-EV controls. Treatment with LY294002 resulted in a decrease of mitochondrial CRC and increase in mitochondrial ROS production and cell apoptosis in the H9c2-hPON2 group versus H9c2-EV controls. CONCLUSION: PON2 protects against acute myocardial IRI by reducing mitochondrial dysfunction and oxidative stress in cardiomyocytes via activation of the PI3K/Akt/GSK-3β RISK pathway.
OBJECTIVE: To investigate the novel role of Paraoxonase 2 (PON2) in modulating acute myocardial ischemia-reperfusion injury (IRI). APPROACH: IRI was induced both in vivo and ex vivo in male, C57BL6/J (WT) and PON2-deficient (PON-def) mice. In addition, in vitro hypoxia-reoxygenation injury (HRI) was induced in H9c2 cells expressing empty vector (H9c2-EV) or humanPON2 (H9c2-hPON2) ± LY294002 (a potent PI3K inhibitor). Infarct size, PON2 gene expression, mitochondrial calcium retention capacity (CRC), reactive oxygen species (ROS) generation, mitochondrial membrane potential, CHOP and pGSK-3β protein levels, and cell apoptosis were evaluated. RESULTS:PON2 gene expression is upregulated in WT mice following in vivo IRI. PON2-def mice exhibit a 2-fold larger infarct, increased CHOP levels, and reduced pGSK-3β levels compared to WT controls. Global cardiac mitochondria isolated from PON2-def mice exhibit reduced CRC and increased ROS production. Cardiomyocytes isolated from PON2-def mice subjected to ex vivo IRI have mitochondria with reduced CRC (also seen under non-IRI conditions), and increased ROS generation and apoptosis compared to WT controls. PON2 knockdown in H9c2 cells subjected to HRI leads to an increase in mitochondrial membrane depolarization. H9c2-hPON2 cells exhibit i) improvement in mitochondrial membrane potential, pGSK-3β levels and mitochondrial CRC, and ii) decrease in CHOP levels, mitochondrial ROS generation and cell apoptosis, when compared to H9c2-EV controls. Treatment with LY294002 resulted in a decrease of mitochondrial CRC and increase in mitochondrial ROS production and cell apoptosis in the H9c2-hPON2 group versus H9c2-EV controls. CONCLUSION:PON2 protects against acute myocardial IRI by reducing mitochondrial dysfunction and oxidative stress in cardiomyocytes via activation of the PI3K/Akt/GSK-3β RISK pathway.
Authors: Hewang Lee; Xiaoliang Jiang; Imran Perwaiz; Peiying Yu; Jin Wang; Ying Wang; Maik Hüttemann; Robin A Felder; David R Sibley; Brian M Polster; Selim Rozyyev; Ines Armando; Zhiwei Yang; Peng Qu; Pedro A Jose Journal: Hypertens Res Date: 2021-04-05 Impact factor: 5.528
Authors: Jacqueline M Garrick; Toby B Cole; Theo K Bammler; James W MacDonald; Judit Marsillach; Clement E Furlong; Lucio G Costa Journal: Neurotoxicol Teratol Date: 2021-07-01 Impact factor: 4.071